Retrophin Reports Positive Top-line Results From Sparsentan Phase 2 DUET Study

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) partner Retrophin, Inc. (RTRX) reported positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis, a kidney disorder without an approved pharmacologic treatment that often leads to end-stage renal disease. The company said the study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period. Top-line results suggest sparsentan was generally safe and well-tolerated in the DUET study.

Retrophin announced it plans to engage the FDA to determine the most expeditious path forward to advance the development of sparsentan towards approval.